Skin Spectrum Quarterly: The Journal of Ethnodermatology™ is a new open-access dermatology journal dedicated to advancing optimal...

Registration is open for the 10th annual Skin Spectrum Summit . The Summit is an educational congress of healthcare professionals...

Extending the dosing interval of guselkumab from eight weeks to sixteen weeks is non-inferior for treating psoriasis in super-responders.

New research has revealed that plastic surgery patients who use marijuana often have elevated nicotine levels, even when they deny using...

Recent research has found smoking cessation significantly reduced the risk of developing hidradenitis suppurativa (HS). The findings were...

Cendakimab is safe and efficacious in treating moderate-to-severe AD in adult patients.

On Aug. 14, World Health Organization (WHO) Director-General Dr. Tedros Adhanom Ghebreyesus declared that the upsurge of the infectious...

Patients with moderate-to-severe PsO are more than twice as likely to take a half-day off work than those with mild psoriasis